Try our mobile app

Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo

Published: 2022-06-04 15:00:00 ET
<<<  go to LLY company page

AWARD-PEDS results presented at ADA's 82nd Scientific Sessions® and simultaneously published in the New England Journal of Medicine demonstrate A1C reductions of up to 1.5% for Trulicity compared to placebo in this underserved population

INDIANAPOLIS, June 4, 2022 /PRNewswire/ -- In the phase 3 AWARD-PEDS clinical trial from Eli Lilly and Company (NYSE: LLY), Trulicity® (dulaglutide) (at 0.75 mg and 1.5 mg doses) led to superior A1C reductions at 26 weeks versus placebo in youth and adolescents (ages 10 to 17 years old) with type 2 diabetes inadequately controlled with diet and exercise, with or without metformin and/or basal insulin. The study, presented in a poster at the American Diabetes Association's® (ADA) 82nd Scientific Sessions and simultaneously published in the New England Journal of Medicine, met all of its primary and secondary glycemic control objectives: percent of patients achieving A1C of